Genomics | Protein Chemistry & Proteomics | Medical Genetics | Renal Immunology & Pathology (incl. Glomerular Diseases) | Methods for Diagnostic & Therapeutic Studies
Urine proteome profile: An attempt to biomarker discovery for the non-invasive diagnosis of IgA nephropathy
Maria Teresa Rocchetti*, Massimo Papale1, Salvatore di Paolo, Grazia Vocino, Ida Valentina Suriano, Giuseppe Grandaliano, Loreto Gesualdo
*Corresponding author: Maria Teresa Rocchetti
Department of Biomedical Sciences-Section of Nephrology, Department of Bioagromed, University of Foggia, Foggia, Italy
F1000Posters 2011, 2: 1177 (poster) [ENGLISH]
Poster [2.85 MB]
Presented at
48th Congress of the European Renal Association and European Dialysis and Transplant Association 2011,
23 - 26 Jun 2011, F-265
In the present study we generated urine proteomic profiles from IgA nephropathy (IgAN) patients by Surface-Enhanced Laser Desorption/Ionization-Time Of Flight/Mass Spectrometry (SELDI-TOF/MS) with the aim to recognize a set of biomarkers possibly allowing the non-invasive diagnosis of the disease.
Urine proteins from 49 biopsy-proven IgAN patients, 42 patients with non-IgA biopsy-proven chronic nephropathies and 36 healthy individuals were analyzed on SELDI-TOF/MS. The dataset was managed by both univariate and supervised statistical analysis.
Univariate analysis identified 11 mass peaks which discriminate IgAN from non-IgAN patients. Among them, 8 of 11 mass peaks also discriminated IgAN patients from healthy individuals (CTRL). Classification and Regression Tree (CART) analysis allowed us to build up a classification tree based on three main predictors that we were able to correctly classify, in the blinded testing set, IgAN and non-IgAN with 88% sensitivity and 72% specificity. A second classification tree based on two main predictors was also able to correctly classify IgAN and CTRL with 90% sensitivity and specificity. Mass peaks were isolated by two-dimensional gel electrophoresis and identified by MALDI-TOF-MS/MS analysis.
Urine proteome analysis can help to identify non-invasive biomarkers to distinguish IgAN from non-IgAN nephropathies.
No relevant conflicts of interest declared.
Please note that most posters on this site present work that is preliminary in nature and has not been peer reviewed.
This poster is open access subject to the CC BY-NC Creative Commons 3.0 License
